Carmelina® is a long-term cardiovascular outcomes trial (CVOT) testing the impact of treatment iwht linagliptin versus placebo, on top of standard of care, on cardiovascular (CV) as well as kidney safety. The sponsor, Boehringer Ingelheim, one of the world’s first pharmaceutical companies, seeks to help support informed treatment decision-making in patients with type 2 diabetes and established CV and/or kidney complications. Visit www.carmelinatrial.com to learn more.

Source: carmelinatrial.com

Pin It on Pinterest